Mizuho Securities analyst Difei Yang maintained a Buy rating on Concert Pharma (CNCE) today and set a price target of $26. The company’s shares closed yesterday at $16.15.
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.4% and a 50.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Concert Pharma has an analyst consensus of Strong Buy, with a price target consensus of $26, which is a 61.0% upside from current levels. In a report issued on March 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
Based on Concert Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $20.85 million. In comparison, last year the company had a GAAP net loss of $6.08 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders.
